Reported Earlier, SAB Biotherapeutics Receives Australian Approval To Commence Phase 1 Clinical Trial Of SAB-142, A Potential Disease-Modifying Treatment For Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
SAB Biotherapeutics (NASDAQ:SABS) has received approval from the Australian Human Research Ethics Committee (HREC) to commence a Phase 1 clinical trial of SAB-142, a potential treatment for Type 1 Diabetes. The company is also planning to file an Investigational New Drug (IND) application with the U.S. FDA. SAB-142 is a fully-human anti-thymocyte immunoglobulin (ATG) that targets immune cells involved in destroying insulin-producing pancreatic beta cells.
October 19, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SAB Biotherapeutics has received approval to commence a Phase 1 clinical trial of SAB-142 in Australia. The company is also planning to file an IND with the U.S. FDA.
The approval to commence a Phase 1 clinical trial of SAB-142 in Australia is a positive development for SAB Biotherapeutics. It indicates progress in the company's product pipeline and could potentially lead to future revenue if the trial is successful. The company's intention to file an IND with the U.S. FDA also suggests potential expansion into the U.S. market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100